Form 4: Director Madhavan Balachandran Executes uniQure Stock Sale
Statement of Changes in Beneficial Ownership
Director Madhavan Balachandran exercised options and sold 10,000 shares of uniQure N.V. under a Rule 10b5-1 trading plan.
Summary
- Director Madhavan Balachandran exercised stock options to acquire 10,000 ordinary shares at a price of $8.49 per share.
- Following the acquisition, the director sold the same 10,000 shares at a weighted average price of $27.85 per share.
- The transactions were executed on June 15, 2026, pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.
- The director's total beneficial ownership in uniQure N.V. stands at 43,254 ordinary shares following these transactions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-established 10b5-1 plan and represents routine portfolio management by a director.
Positives
- The transaction was pre-planned under a Rule 10b5-1 plan, indicating the sale was not based on non-public information.
- The director maintains a significant remaining stake of 43,254 shares in the company.
Negatives
- The director reduced their total beneficial ownership position by 10,000 shares.
Risks
- Insider selling can sometimes be perceived negatively by the market, though this was part of a pre-arranged plan.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that insider transactions in the biotechnology sector are common and often follow pre-arranged 10b5-1 plans to provide liquidity for executives and directors, and this filing reflects standard corporate governance practices.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate insiders to sell shares while avoiding potential allegations of insider trading.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was pre-planned and executed at market prices.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 09/20/2021 | Date the stock options fully vested. |
| 03/10/2026 | Date the Rule 10b5-1 sales plan was adopted. |
| 06/15/2026 | Date of the option exercise and subsequent share sale. |
| 06/17/2026 | Date the Form 4 was signed and filed. |
Keywords
uniQure, QURE, insider trading, Form 4, biotech, stock options
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.